hrp0082p2-d1-455 | Growth | ESPE2014

The Effect of Long Term GH Therapy in Discordant Twins Where One Twin is Born Small for Gestational Age: A Case Control Study

Letshwiti Johannes , O'Mullane Elaine , Hoey Hilary , Roche Edna

Background: The positive effect of GH therapy in small for gestational age (SGA) singletons has been shown in previous studies. Little is known about twin growth and GH treatment where only one twin is born SGA.Objective and hypotheses: We present data from two set of twins where one was appropriate for gestational age (control) and the other twin was SGA (treatment).Method: Twin pair 1: male monochorionic diamniotic (MCDA) twins b...

hrp0095p1-46 | Diabetes and Insulin | ESPE2022

The incidence of Type 1 diabetes mellitus has stopped falling and is rising again in Ireland – a preliminary report from the Irish Childhood Diabetes National Register

Roche Edna , McKenna Amanda , Ryder Kerry , Fitzgerald Helen , Hoey Hilary , O'Regan Myra

Introduction and Aim: The Incidence of Type 1 diabetes mellitus (T1DM) varies markedly between populations and over time. Recently a number of high incidence countries, including Ireland, have reported a stabilisation and/or reduction in their T1DM incidence rate (IR) in childhood. Ireland, a high incidence country for T1DM, experienced a dramatic increase in T1DM incidence between 1997 and 2008, a stabilisation in incidence between 2014 and 2018 followed by a...

hrp0082p1-d3-88 | Diabetes (2) | ESPE2014

Improved Health-related Quality of Life with Insulin Therapy in Children with Cystic Fibrosis-related Diabetes: a Prospective Cohort Study

George Sherly , Hoey Hilary M C V , Costigan Colm , Murphy Nuala , Roche Edna F , O'Riordan Stephen M P

Background: Cystic fibrosis-related diabetes (CFRD) is a common complication in cystic fibrosis (CF). CFRD symptoms and treatment may impose additional burden and adversely affect their QoL.Objective and hypotheses: Assess HRQoL in CF children with normal glycaemia (CFN) and CFRD and evaluate the change in HRQoL over 1 year period along with clinical changes.Method: A prospective study was undertaken including children aged 10&#150...

hrp0092rfc14.5 | Adrenals and HP Axis | ESPE2019

Bioactive IGF-I Concentration Compared to Total IGF-I Concentration Before and After 1 Year of High-Dose Growth Hormone in Short Children Born Small for Gestational Age - North European SGA Study (NESGAS)

Beck Jensen Rikke , Gersel Wegmann Mathilde , Thankamony Ajay , Roche Edna , Hoey Hilary , Kirk Jeremy , Ivarsson Sten-A. , Söder Olle , Frystyk Jan , Dunger David B. , Juul Anders

Background: Children born small for gestational age (SGA) exhibit wide variations in the activity of growth hormone (GH)/insulin–like growth factor–I (IGF-I) axis and this heterogeneity may result in supra physiological concentrations of IGF-I during GH treatment. The long-term effects of elevated IGF-I levels has been a matter of concern. We explored the variations in total IGF-I and bioactive IGF-I and the associations with growth and glucose metab...

hrp0082fc7.1 | Growth promoting therapies | ESPE2014

Genetic Markers of Insulin Resistance are Associated with GH Response in Short SGA Children: the North European SGA Study

Jensen Rikke Beck , Thankamony Ajay , Day Felix , Kirk Jeremy , Donaldson Malcolm , Ivarsson Sten-A , Soder Olle , Roche Edna , Hoey Hilary , Juul Anders , Ong Ken , Dunger David

Background: There is wide heterogeneity in responses to GH treatment in children born small for gestational age (SGA).Objective and Hypotheses: The aim was to explore the impact of genetic markers on glucose metabolism and growth during first year high-dose GH treatment in SGA children.Method: In North European Small for Gestational Age Study (NESGAS) patients received high-dose GH (67 μg/kg per day) the first year. 97 patient...